Roche Diagnostics Limited acquires LumiraDx Group Limited (in administration) and LumiraDx International Limited (in administration) (2024)

Deal facts

Buyer: Roche Diagnostics Limited
Target: LumiraDx Group Limited (in administration) and LumiraDx International Limited (in administration)
Deal value: Not disclosed
Announced: 23 May 2024
Status: In review
Sector: Healthcare
Country: United Kingdom
Consideration: Not stated

Sources

UK_CMA_GOVUK

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

20 May 2024CMA Phase 1 launched
Roche / LumiraDx merger inquiry
The CMA has investigated the anticipated acquisition by Roche Diagnostics Limited of certain entities held by LumiraDx Group Limited (in administration) and LumiraDx International Limited (in administration) Statutory timetable Phase 1 Action 19 July 2024 Decision announced 23 May 2024 Launch of merger inquiry 20 May 2024 to 3 June 2024 Invitation to comment
UK CMA

OpinionExit Mode editorial

We see a clear signal in the announcement that Roche Diagnostics Limited is moving to acquire LumiraDx Group Limited and LumiraDx International Limited, both currently in administration. This strategic acquisition within the healthcare sector demonstrates how major players position themselves to secure critical intellectual property and market access when a target faces insolvency. The deal structure is distinct because it bypasses the traditional equity sale, moving instead through the administration process to salvage value from distressed assets. For the SME founder watching from the sidelines, this scenario highlights that a distressed exit can still deliver strategic continuity if the buyer identifies genuine long-term value in the technology or customer base.

The fact that the transaction remains in review suggests that regulatory clearance is a necessary step before completion. Given the domestic nature of this UK to UK deal, the Competition and Markets Authority will likely assess whether the acquisition reduces competition in the diagnostic testing market or creates a monopoly on specific platforms. While the value remains undisclosed, the mechanics of buying out of administration often involve strict timelines and the need to satisfy creditor claims before any equity value can be realised. The buyer must navigate change-of-control covenants and ensure that key staff and contracts transfer smoothly without triggering termination clauses that could devalue the asset.

This move underscores the importance of having a viable strategic buyer ready even when the balance sheet is under pressure. It is not uncommon for administration to act as a catalyst for a sale that might otherwise have stalled during private negotiations. The regulatory context here is vital, as the CMA review period introduces a defined window of uncertainty that both parties must manage carefully. Failure to secure clearance could force the administrator to seek alternative buyers or liquidate assets piecemeal, which rarely serves the original founders or employees well.

Your immediate action this week should be to review your own change-of-control covenants and identify which key contracts might trigger termination if your company were to enter administration. Map out the specific regulatory thresholds that apply to your sector and prepare a briefing for your board on how a distressed sale would be viewed by the Competition and Markets Authority.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More strategic acquisition deals More from Roche Diagnostics Limited All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history